A flow injection system with in-series ultraviolet and electrochemical detection for the simultaneous determination of lovastatin and butylated hydroxyanisole in a tablet.
A flow injection (FI) method has been developed to determine simultaneously a drug with an ultraviolet chromophore, lovastatin, and butylated hydroxyanisole (BHA) in a tablet. The system involves ultraviolet (UV) absorbance detection for the drug and oxidative amperometric electrochemical detection for BHA. The method has been shown to be reproducible for routine determinations with an accuracy of +/-1% for lovastatin and +/-4% for BHA. Precision for both analytes was approximately +/-1% (RSD). The use of FI compared with HPLC for these determinations has led to a dramatic decrease in the time required per assay. The method with UV detection has been shown to be specific for the drug in the presence of potential autoxidation products as well as BHA and its oxidation products. The use of electrochemical detection in series allows the method to be simultaneously specific for low levels of BHA (40 microg/tablet) in the presence of its oxidation products as well as the drug and its potential autoxidation products.
Mazzo
D J
DJ
Department of Pharmaceutical Research and Development, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486, USA.
Biffar
S E
SE
Forbes
K A
KA
Bell
C
C
Brooks
M A
MA